活動報告

論文発表

2004年～2009年発表論文

2021年9月1日

任意団体としての研究論文は以下の通りです

Characteristics of Patients with Prostate Cancer Who have Initially been Treated by Hormone Therapy in Japan: J-CaP Surveillance
- H.Akaza, M.Usami, S.Hinotsu,O.Ogawa, S.Kagawa,T.Kitamura, T.Tsukamoto,S.Naito, Y.Hirao,M.Murai, H.Yamanaka
- Jpn J Clin Oncol 2004; 34(6)329-336
- https://doi.org/10.1093/jjco/hyh061ka

The Case for Androgen Deprivation as Primary Therapy for Early Stage Disease: Results From J-CaP and　CaPSURE　
- H.Akaza, S.Hinotsu, M.Usami,O.Ogawa, S.Kagawa, T.Kitamura,T.Tsukamoto, S.Naito, Y.Hirao,M.Murai, H.Yamanaka, M.Namiki
- Int J Urol 2007; 14(3)192-196
- http://www.ncbi.nlm.nih.gov/pubmed/17084166

Prostate specific antigen half-life and pretreatment prostate-specific antigen: Crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy
- N.Soga, T.Onishi, K.Arima, Y.Sugimura
- Int J Urol 2007; 14(3)192-196
- http://www.ncbi.nlm.nih.gov/pubmed/17430253
Current Status of Endocrine Therapy for Prostate Cancer in Japan ―Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP
- S.Hinotsu, H.Akaza, M.Usami,O.Ogawa, S.Kagawa, T.Kitamura,T.Tsukamoto, S.Naito, M.Namiki,Y.Hirao, M.Murai, H.Yamanaka,and The Japan Study Group of Prostate Cancer (J-CaP)
- Jpn J Clin Oncol 2007; 37(10)775-781
- http://www.ncbi.nlm.nih.gov/pubmed/17965423

Undetectable Level of Prostate Specific Antigen (PSA) Nadir Predicts PSA Biochemical Failure in Local Prostate Cancer with Delayed-combined Androgen Blockade
- N.Soga, K.Arima, Y.Sugimura
- Jpn J Clin Oncol 2008; 38(9)617-622
- http://www.ncbi.nlm.nih.gov/pubmed/18697759

Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy
- MR.Cooperberg, S.Hinotsu, M.Namiki, K.Ito, J.Broering, PR.Carroll, H.Akaza
- J Clin Oncol.2009 Sep 10;27(26):4306-13.
- https://doi.org/10.1200/jco.2008.21.5228